Vaxess Technologies, Inc. is a pioneering life sciences company focused on the development of innovative vaccine and therapeutic delivery technologies. Their flagship product, the MIMIX™ platform, is a cutting-edge transdermal patch system that aims to make vaccines and therapeutics more effective and accessible, particularly in challenging environments.
The MIMIX™ platform is an innovative transdermal patch delivery system that utilizes dissolvable microarray technology to administer vaccines and therapeutics painlessly. Each patch is composed of microarray tips made from silk fibroin proteins, which dissolve upon application to the skin, ensuring a controlled and sustained release of the active ingredients over time to enhance immune responses.
The MIMIX™ platform addresses critical challenges in vaccine and drug delivery, such as the necessity for refrigeration and the discomfort associated with needles, thereby improving vaccination accessibility and user adherence.
Vaxess addresses significant pain points such as the cold chain logistics required for vaccine transportation and storage, the discomfort associated with traditional needle delivery, and the complications involved in administering biologics.